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Background: Our objective was to associate serum levels of myocardial enzymes and 
inﬂ  ammatory biomarkers with severity of coronary artery disease (CAD).
Patients and methods: 123 patients participated in our study, including 65 cases of 
acute myocardial infarction (MI), 27 cases of newly diagnosed CAD – without MI – and 31 
controls. In all subjects, myocardial serum enzyme levels (creatine phosphokinase, aspartate 
aminotransferase, lactate dehydrogenase) and inﬂ  ammatory indices (C-reactive protein, 
ﬁ  brinogen, white blood cells, and erythrocyte sedimentation rate) were measured. Patients were 
all submitted to coronary angiography and CAD severity was evaluated by Gensini score.
Results: Signiﬁ  cant differences concerning enzyme serum levels and inﬂ  ammatory indices 
were found to exist between the three study groups, being highest among patients with acute 
MI (p  0.001). A signiﬁ  cant association was demonstrated between Gensini score and serum 
enzyme levels as well as inﬂ  ammatory biomarkers.
Conclusions: Our ﬁ  ndings suggest that serum levels of myocardial enzymes and inﬂ  ammatory 
indices correlate with CAD severity in Greek patients.
Keywords: myocardial enzymes, inﬂ  ammation, coronary angiography, coronary artery 
disease
Background
Acute coronary syndromes including ST-elevation myocardial infarction (STEMI) 
and Non-ST elevation myocardial infarction (NSTEMI) are known to be associated 
with elevated serum levels of myocardial enzymes, including troponin, total creatine 
phospokinase (CPK), the myocardial isoenzyme of CPK (CPK-MB), aspartate 
aminotransferase (AST) and lactate dehydrogenase (LDH). Unstable angina pectoris 
is also included in acute coronary syndromes as a harbinger of imminent myocardial 
necrosis in the setting of either STEMI or NSTEMI. Myocardial enzyme levels are 
used in both clinical and laboratory settings in order to establish a diagnosis of an acute 
coronary syndrome, apart from electrocardiographic and clinical ﬁ  ndings (Möckel et al 
1998; Panteghini 2004; Antman et al 2004; Melanson et al 2007; Morrow et al 2007).
The inﬂ  ammatory process initiated by myocardial tissue necrosis (Neumann et al 
1995) is also related to an increase of nonspeciﬁ  c serum markers such as C-reactive 
protein (CRP) (Mendall et al 2000; Blake and Ridker 2003; Brunetti et al 2006), 
ﬁ  brinogen (Eidelman and Hennekens 2003; Manilla 2006; Omran and Asadollahi 
2007), peripheral white blood cell count (WBC) (Madjid et al 2004; Jia et al 2005), 
and erythrocyte sedimentation rate (ESR) (Erikssen et al 2000) above normal limits.Clinical Interventions in Aging 2008:3(4) 700
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Severity of coronary artery disease (CAD) is optimally 
assessed by means of coronary angiography where the 
number of epicardial coronary vessels affected, the 
anatomical distribution of critical stenotic lesions and 
the extent of vascular ﬂ  ow impairment is demonstrated 
(Conti 1977; Gensini 1980). Coronary angiography remains 
the standard for assessment of anatomic coronary disease, 
because no other currently available test can accurately 
deﬁ  ne the extent of coronary luminal obstruction. Coronary 
angiography is principally used in three clinical situations: 
(i) to determine the presence and extent of obstructive CAD 
in a setting in which the diagnosis is uncertain and CAD 
cannot be reasonably excluded by noninvasive testing; 
(ii) to assess the feasibility and appropriateness of various 
forms of therapy, such as revascularization by percutaneous 
or surgical interventions; and (iii) as a research tool for the 
assessment of treatment results and the progression or regres-
sion of coronary atherosclerosis (Scanlon et al 1999). The 
Gensini scoring system is a valuable aid, used to estimate 
the gravity of CAD according to angiographic ﬁ  ndings, 
taking into account the anatomical location and the degree 
of coronary vessel stenoses. Gensini score calculation is 
based on the evaluation of the number of stenotic coronary 
artery segments, the degree of their lumen stenosis and the 
localization of stenotic changes (Gensini 1983).
Limited information is available regarding the correlation 
between myocardial enzyme serum levels and inﬂ  ammatory 
markers with the extent and severity of CAD, as it is estimated 
by Gensini score in Greek patients submitted to coronary 
angiography. A prospective, observational, case control study 
was performed in a total of 123 hospitalized patients at the 
Department of Clinical Therapeutics, Alexandra Hospital 
between September 2005 and September 2007. The objective 
was to identify correlations between myocardial enzyme 
serum levels, inﬂ  ammatory biomarkers, and coronary angi-
ography ﬁ  ndings, represented by Gensini score.
Patients and methods
Study population
Among the study population, there were 65 cases of ﬁ  rst-ever 
acute myocardial infarction (MI) (STEMI and NSTEMI), 
and 27 cases of newly-diagnosed CAD without evidence of 
MI in the past or during hospitalization. There were also 31 
cases with negative angiographic ﬁ  ndings that comprised 
the control group of patients. Cases of acute, ﬁ  rst-ever MI 
included 42 male patients (34.1% of total study population) 
with mean age of 60 ± 10.9 years. Cases of newly-diagnosed 
CAD without MI included 17 male patients (13.18% of total 
study population) with mean age of 64 ± 11 years. Finally, 
subjects with negative coronary angiography (control group) 
included 7 male patients (5.6% of total study population) with 
mean age of 64.3 ± 10.5 years (Table 1). Cases in all three 
patient subgroups were matched for age, body mass index 
(BMI), and waist-to-hip ratio (WHR) (Table 1).
In order to perform our study, a convenience sample 
of patients sequentially hospitalized between September 
2005 and September 2007 that were submitted to coro-
nary angiography, was selected. Patients in the control 
group were submitted to coronary angiography as part of a 
detailed diagnostic workup for a variety of conditions. The 
main reasons of hospitalization for controls were either 
atypical chest pain with ambiguous exercise stress testing 
Table 1 Baseline characteristics of the study population. All three patient subgroups are matched for age, BMI, and WHR.   There was 
a signiﬁ  cant difference in the prevalence of male sex, smoking habits, arterial hypertension, hyperlipidemia, and family history of CAD 
between patient subgroups (see details in text)
Acute ﬁ  rst-ever myocardial 
infarction (STEMI & NSTEMI)
Coronary artery disease 
(no myocardial infarction)
Controls p
N6 5 2 7 3 1
Male 42 (34.1)* 17 (13.8) 7 (5.6) 0.001
Mean age (Years) 60 ± 10.9 64 ± 11 64.3 ± 10.5 0.113
Smoking 38 (30.8) 15 (12.2) 10 (8.1) 0.049
Hypertension 41 (33.3) 23 (18.7) 25 (20.3) 0.048
Diabetes mellitus 12 (9.7) 10 (8.1) 6 (4.8) 0.134
Hyperlipidemia 60 (48.7) 26 (21.1) 19 (15.4) 0.001
Family History of CAD 23 (18.7) 2 (1.6) 9 (7.6) 0.023
Alcohol consumption 4 (3.2) 2 (1.6) 1 (0.8) 0.769
Hyperuricemia 18 (14.6) 7 (5.6) 6 (4.8) 0.676
*Numbers in brackets indicate corresponding percentages of the total study population.Clinical Interventions in Aging 2008:3(4) 701
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results (N = 18, 58%), or presurgical evaluation for severe 
valvular disorders – aortic stenosis, mitral stenosis, mitral 
incompetence – (N = 6, 19.4%), dilated or hypertrophic 
cardiomyopathy (N = 3, 9.7%), and nonsustained ventricular 
tachycardia (N = 1, 3.2%).
Methods
A detailed medical history, physical examination, 
electrocardiogram, hematologic and biochemical screening 
was performed in all patients during hospitalization. In all 
three groups of patients, laboratory evaluation of total CPK, 
AST, LDH, CRP, ﬁ  brinogen, WBC count, and ESR was 
performed in the ﬁ  rst 48 h during hospital stay. Although 
serum troponin I test was qualitatively evaluated and regarded 
as either “positive”, indicating increased serum levels 
or “negative”, assuming normal serum levels, no further 
quantitative determination of troponin I was performed due to 
laboratory limitations. Serial biochemical and hematological 
assays were performed, yet peak serum levels of myocardial 
enzymes and inﬂ  ammation markers were utilized in our 
analyses.
All patients were submitted to coronary angiography 
during hospitalization, either on an emergency basis or as 
part of a scheduled diagnostic workup. Patients in all study 
subgroups had no underlying systemic disease that could 
affect serum inﬂ  ammatory biomarker proﬁ  le apart from 
cardiological conditions. Consequently, all measurements 
reﬂ  ect the impact of CAD upon enzyme and inﬂ  ammatory 
biomarker levels.
The Gensini scoring system was utilized in the evaluation 
of CAD severity. The Gensini score was calculated for each 
patient from the coronary arteriogram by assigning a severity 
score to each coronary stenosis according to the degree of 
luminal narrowing and its geographic importance. Reduction 
in the lumen diameter, and the roentgenographic appearance 
of concentric lesions and eccentric plaques were evaluated 
(reductions of 25%, 50%, 75%, 90%, 99%, and complete 
occlusion were given Gensini scores of 1, 2, 4, 8, 16, and 32, 
respectively). Each principal vascular segment was assigned 
a multiplier in accordance with the functional signiﬁ  cance of 
the myocardial area supplied by that segment: the left main 
coronary artery × 5; the proximal segment of left anterior 
descending coronary artery (LAD) × 2.5; the proximal 
segment of the circumﬂ  ex artery × 2.5; the mid-segment of 
the LAD × 1.5; the right coronary artery, the distal segment 
of the LAD, the posterolateral artery and the obtuse marginal 
artery × 1; and others × 0.5. Scoring was performed by two 
observers and averaged (Hayashi et al 2003).
Assesment of risk factors 
and comorbidities
A positive family history was sought in all patients with a ﬁ  rst 
degree relative with evidence of CAD. Smoking habits and 
alcohol consumption was also recorded. Hypertensive patients 
were identiﬁ  ed in the basis of receiving antihypertensive 
treatment before hospital admission or whether blood pres-
sure exceeded 140/90 mmHg in at least three measurements. 
Patients with diabetes mellitus were identiﬁ  ed in the basis of 
receiving oral hypoglycemic medications or insulin, or hav-
ing fasting glucose levels above 126 mg/dl. Hyperlipidemia 
was identiﬁ  ed in patients already on hypolipidemic treatment, 
or in patients with acute MI or CAD (without infarction) or 
diabetes mellitus with low-density lipoprotein 100 mg/dl. 
Patients with triglyceride levels above 150 mg/dl were also 
regarded as being hyperlipidemic.
Baseline characteristics of the study population are 
demonstrated in Table 1.
Statistical analysis
Chi-square test was performed to detect differences in 
the prevalence of classic cardiovascular risk factors 
(smoking, hypertension, diabetes mellitus, hyperlipidemia, 
family history of CAD) between the three patient groups. 
Analysis of variance (ANOVA) was performed in order to 
identify differences concerning mean serum enzyme levels 
and inflammatory biomarkers between patient groups. 
Bivariate correlation analysis was conducted in order to 
detect correlation of myocardial enzyme serum levels 
and inﬂ  ammatory markers with Gensini score. SPSS 13.0 
statistical software (SPSS Inc., Chicago, IL) was used in the 
analysis performed.
Results
A statistically signiﬁ  cant difference in the prevalence of 
male sex, smoking habits, hypertension, hyperlipidemia, 
and family history of CAD was found to exist among the 
three patient groups. In particular, male sex predominated in 
patients with acute ﬁ  rst-ever MI (N = 42) and CAD without 
MI (N = 17) in comparison with the control group (N = 7), 
(p  0.001), (Table 1).
No significant differences between patient groups 
regarding mean age, BMI and WHR were observed. In 
particular, patients with acute, ﬁ  rst-ever MI had mean age 
60 ± 10.9 years whereas patients with CAD without MI had 
mean age 64 ± 11 years and control subjects had mean age 
64,3 ± 10.5 years, respectively (p = 0.113 , 95% CI) (Table 1). 
Patients with acute, ﬁ  rst-ever MI had mean BMI values of Clinical Interventions in Aging 2008:3(4) 702
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27.4 ± 3.69 kg/m2 and mean WHR values of 0.95 ± 0.08 
while patients with CAD without MI had mean BMI values 
of 27.7 ± 5.24 kg/m2 and mean WHR values of 0.93 ± 0.07. 
Control subjects had mean BMI 29.2 ± 5 kg/m2 and mean 
WHR 1.07 ± 0.97. No signiﬁ  cant differences regarding BMI 
(p = 0.219 , 95% CI) or WHR (p = 0.511, 95% CI) were found 
between patient subgroups (Table 1).
The prevalence of tobacco use was signiﬁ  cantly higher 
in patients with acute ﬁ  rst-ever MI (N = 38) and CAD 
without MI (N = 17) compared with the controls (N = 7), 
(p = 0.049) (Table 1). Similarly, the prevalence of hyperten-
sion, hyperlipidemia and positive family history of CAD 
was found to be higher in patients with acute MI and CAD 
without MI, in contrast with controls (p = 0.048, p  0.001 
and p = 0.023 respectively; Table 1). Diabetes mellitus and 
hyperuricemia were observed in higher proportion of patients 
with acute MI and CAD without MI, in contrast with controls, 
yet the difference did not achieve statistical signiﬁ  cance 
in our study sample. (p = 0.13 and p = 0.67 respectively; 
Table 1). Baseline characteristics of the study population 
are shown in Table 1.
Mean levels of CPK, AST, and LDH were signiﬁ  cantly 
higher in patients with acute ﬁ  rst-ever MI compared with 
patients with CAD without MI and controls. Mean serum 
CPK value was in the range of 1.241 ± 1.459 IU/L for 
patients with acute MI, 59 ± 21 IU/L for patients with CAD 
without MI and 62 ± 30 IU/L for controls (p  0.001, 95% 
CI; Table 2). Similarly, mean serum AST was 154 ± 141 IU/L 
and mean serum LDH was 610 ± 523 IU/L in patients with 
acute MI, while patients with CAD but no MI had mean levels 
of AST 20 ± 8 IU/L and LDH 188 ± 67 IU/L. Control patients 
had mean serum AST 19 ± 7 IU/L and LDH 193 ± 44 IU/L. 
(p  0.001 and p  0.001 respectively, 95% CI, Table 2). 
Apparently, patients with acute MI had signiﬁ  cantly higher 
levels of CPK, AST, and LDH compared to patients in the 
other two groups (Table 2).
Mean values of CRP and peripheral WBC counts 
were signiﬁ  cantly higher in patients with acute MI than in 
patients with CAD without MI and controls. In particular, 
mean CRP levels were 4.7 ± 5.5 mg/dl, 0.8 ± 0.6 mg/dl, 
and 0.77 ± 0.5 mg/dl, respectively (p  0.001; Table 2). 
Mean peripheral WBC counts were signiﬁ  cantly higher in 
patients with acute MI (11.216 ± 3.496/mm3) compared with 
patients with CAD without MI (8.162 ± 2.456/mm3) and con-
trols (7.648 ± 1.903/mm3), (p  0.001; Table 2). Fibrinogen 
levels and ESR were higher in patients with acute MI com-
pared to other groups, yet the difference did not yield statisti-
cal signiﬁ  cance in our study sample (p = 0.14 and p = 0.33, 
respectively; Table 2). Regarding serum lipid proﬁ  le, although 
mean HDL levels were higher in controls (64 ± 33 mg/dl) in 
comparison with patients with CAD without MI (48 ± 11 mg/dl) 
and patients with acute MI (55 ± 29 mg/dl), the difference 
Table 2 Mean values ± SD of biochemical, hematological parameters and Gensini score of patient subgroups. Peak serum myocardial 
enzymes (total CPK, AST, and LDH), inﬂ  ammatory markers (CRP, peripheral blood WBC) and Gensini score were signiﬁ  cantly higher 
in patients with acute, ﬁ  rst-ever MI
 Acute  ﬁ  rst-ever 
myocardial infarction 
(STEMI & NSTEMI)
Coronary artery disease 
(no myocardial infarction)
Controls p
Hb (g/dl) 13.6 ± 1.44 13.3 ± 1.54 12.93 ± 1.56 0.12
PLT (/μL) 246.531 ± 102.879 213.920 ± 41.819 251.933 ± 58.215 0.18
WBC (/μL) 11.216 ± 3.496 8.162 ± 2.456 7.648 ± 1.903 0.001
CPK (IU/L) 1241.6 ± 1.459 59.4 ± 21 62.8 ± 30.6 0.001
AST (IU/L) 154.2 ± 141.7 20.1 ± 8.3 19.7 ± 7 0.001
LDH (IU/L) 610.6 ± 513.4 188.6 ± 67.8 193.5 ± 44.8 0.001
CRP (mg/dl) 4.77 ± 5.54 0.88 ± 0.6 0.77 ± 0.5 0.001
ESR (mm) 39.9 ± 28.7 30.2 ± 25.9 31.8 ± 20.9 0.33
Fibrinogen (mg/dl) 434.1 ± 161 374.6 ± 96 371 ± 139.3 0.14
Total Cholesterol (mg/dl) 207 ± 43 200 ± 36 207 ± 33 0.75
HDL (mg/dl) 55 ± 29 48 ± 11 64 ± 33 0.13
LDL (mg/dl) 140 ± 58 130 ± 31 129 ± 30 0.5
Triglycerides (mg/dl) 147 ± 79 158 ± 101 136 ± 99 0.68
Gensini Score 37.4 ± 31.5 36.67 ± 35 0.5 ± 1.3 0.001Clinical Interventions in Aging 2008:3(4) 703
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did not achieve statistical signiﬁ  cance in our study population 
(p = 0.13; Table 2). Similarly, mean LDL levels were highest 
in patients with acute MI (140 ± 58 mg/dl), in contrast with 
patients with CAD without MI (130 ± 31 mg/dl) and controls 
(129 ± 30 mg/dl), but no statistically signiﬁ  cant difference was 
noted in our study sample (Table 2). Mean Gensini score was 
higher in patients with acute MI (37.4 ± 31.5) than in patients 
with CAD without MI (36.67 ± 35) and controls (0.5 ± 1.3), 
(p  0.001, 95% CI; Table 2).
No signiﬁ  cant differences regarding cardiac enzymes, 
inﬂ  ammatory biomarkers, or Gensini score were noted 
between patients with STEMI and NSTEMI consequently 
allowing their incorporation in the same study subgroup under 
the general term “acute ﬁ  rst-ever myocardial infarction.”
Bivariate correlation analysis was performed in the 
whole study sample concerning myocardial enzyme 
levels (CPK, AST, LDH) and inﬂ  ammatory indices (CRP, 
ﬁ  brinogen, WBC count, ESR) with Gensini score, in order 
to establish a possible quantitative association of the latter 
with severity of CAD. In particular, signiﬁ  cant positive 
linear between CPK and Gensini score was demonstrated 
(Spearman’s ρ = 0.389, correlation coefﬁ  cient = 0.389, 
p  0.001). The same positive correlation was for AST 
and LDH with Gensini score (Spearman’s ρ = 0.391, cor-
relation coefﬁ  cient = 0.391, p  0.001, and Spearman’s 
ρ = 0.366, correlation coefﬁ  cient = 0.366, p  0.001, 
respectively). Therefore, higher myocardial enzyme levels 
were related to increased severity of CAD, according to 
Gensini score (Figure 1). Serum HDL levels were inversely 
correlated with both Gensini score (Spearman’s ρ = −0.205, 
correlation coefﬁ  cient = −0.205, p = 0.031) and CRP levels 
(Spearman’s ρ = −0.294, correlation coefﬁ  cient = −0.294, 
p = 0.004; Figure 2). Therefore, a reciprocal relation 
between high-density lipoprotein (HDL) levels and sever-
ity of CAD (Gensini score) and between serum HDL 
and CRP levels was observed (Figure 2). Significant 
correlation was also found regarding CRP and ﬁ  brinogen 
levels with Gensini score (Spearman’s ρ = 0.418, correlation 
coefﬁ  cient = 0.418, p  0.001 and Pearson correlation = 0.224, 
correlation coefﬁ  cient = 0.143 p = 0.037, respectively). 
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The same seemed to apply for WBC count and ESR with 
Gensini score (Spearman’s ρ = 0.258, correlation coefﬁ  -
cient = 0.258, p = 0.004 and Spearman’s ρ = 0.270, correlation 
coefﬁ  cient = 0.270, p = 0.015, respectively; Figure 3).
In addition, the latter correlations seemed to apply for each 
study subgroup of patients. In particular in patients with acute 
ﬁ  rst-ever MI a positive association between both total serum 
CPK and CRP with Gensini score was identiﬁ  ed (correlation 
coefﬁ  cients 0.156 and 0.291, respectively) while a reciprocal 
association between serum HDL and Gensini score was shown 
(correlation coefﬁ  cient = −0.76) (Figure 4). In patients with 
newly-diagnosed CAD without MI positive correlations between 
total serum CPK and CRP with Gensini score were demonstrated 
(correlation coefﬁ  cients = 0.129 and 0.187, respectively) and a 
reciprocal association between serum HDL and Gensini score 
was also noted (correlation coefﬁ  cient = −0.22) (Figure 5).
Discussion
In our study, a statistically significant difference in the 
prevalence of male sex was observed between the three study 
groups, being higher among patients with acute, ﬁ  rst-ever MI 
and CAD without MI, in comparison with controls (p  0.001). 
Male sex is a well recognized risk factor for coronary athero-
sclerosis since there is a signiﬁ  cantly lower age-speciﬁ  c risk 
of CAD in women than men (Mosca et al 1997).
Our study revealed an increased prevalence of tobacco 
smoking among patients with acute, first-ever MI and 
CAD without MI, in comparison with controls (p = 0.049). 
These ﬁ  ndings are in accordance with previous large popu-
lation-based epidemiological studies. In the Western Col-
laborative Group Study, the risk of CAD was signiﬁ  cantly 
associated both with current and former cigarette usage. 
The incidence of new clinical coronary heart disease (CHD) 
was strongly associated with smoking history and with the 
number of cigarettes smoked (Jenkins et al 1968). In a study 
of Japanese patients (Yasue et al 2006) low-grade inﬂ  amma-
tion, atherogenic dyslipidemia, and hypercoagulability were 
present in smokers compared with those who have never 
smoked among subjects without apparent inﬂ  ammation who 
underwent coronary angiography on suspicion of CAD.
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In our study, the prevalence of arterial hypertension was 
also signiﬁ  cantly higher among patients with acute, ﬁ  rst-
ever MI and CAD without MI, in comparison with controls 
(p = 0.048). Prospective longitudinal analysis of follow-up 
data from the Framingham Study of the relation of antecedent 
blood pressure to occurrence of subsequent cardiovascular 
morbidity and mortality depending on the metabolically 
linked burden of associated risk factors has shown that hyper-
tension is one of the most prevalent and powerful contributors 
to cardiovascular diseases (Kannel 1996; Vasan et al 2002).
Hyperlipidemia was noticed in higher proportion in the 
ﬁ  rst two study groups in contrast with controls. A highly 
signiﬁ  cant difference in the prevalence of hyperlipidemia 
was noted, especially in patients with acute MI (p  0.001). 
Hyperlipidemia is considered to be among the major cardio-
vascular risk factors. The role of serum cholesterol in predict-
ing ﬁ  rst coronary events is well established and reduction of 
serum cholesterol decreases the risk of CAD (Castelli et al 
1986; Martin et al 1986; Anderson et al 1987; Pekkanen et al 
1990; Law et al 1994a, 1994b; Gotto Jr 1998).
A strong association of positive family history with 
evidence of CAD was observed in our study. Patients with 
acute MI, had an increased prevalence of family history of 
cardiovascular disease in comparison with the other patient 
groups (p = 0.023). An early history of parental MI (less 
than 60 years of age) confers a greater risk of cardiovascular 
disease than does MI at older ages (Colditz et al 1991; Lloyd-
Jones et al 2004).
Diabetes mellitus, a major cardiovascular risk factor was 
present in higher proportion of patients with acute MI and 
CAD without MI, in comparison with patients in the control 
group, but the difference observed was not signiﬁ  cant in our 
sample (p = 0.134). Diabetes mellitus constitutes a major 
risk factor for cardiovascular events. Based on 20 years 
of surveillance of the Framingham cohort, which related 
subsequent cardiovascular events to prior evidence of dia-
betes, a 2–3-fold increased risk of clinical atherosclerotic 
disease including coronary heart disease, peripheral arterial 
disease, and congestive heart failure was reported (Kannel 
and McGee 1979; Fox et al 2007).
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Figure 5 Scatter plots of peak serum CPK (IU/L), CRP (mg/dl), and HDL (mg/dl) with Gensini score in patients with newly-diagnosed CAD without MI. In this subgroup of patients, 
positive correlations between peak serum CPK and CRP with Gensini score were determined. Negative correlation between serum HDL and Gensini score was also identiﬁ  ed.
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Hyperuricemia (serum uric acid levels 7 mg/dl) was 
present in higher proportion in patients with acute, ﬁ  rst-
ever MI and patients with CAD without MI in comparison 
with controls. A difference was noticed, yet it did not yield 
statistical signiﬁ  cance in our study sample (p = 0.676). 
Evidently, there seems to be an association between serum 
uric acid levels and CAD, since data from Health Profes-
sionals Follow-Up Study indicate that men with gout have 
a higher risk of death from all causes. Among men without 
preexisting CAD, the increased mortality risk is primarily a 
result of an elevated risk of cardiovascular death, particularly 
from CAD (Choi and Curhan 2007).
The process of myocardial tissue necrosis is accompanied 
by elevations in enzyme serum levels of CPK, AST, LDH, 
and troponin due to myocardial cellular damage. Cardiac 
troponin (cTn) has established itself ﬁ  rmly as the “gold 
standard” in the diagnosis of acute coronary syndrome 
and is measured in all patients presenting with symptoms 
suggestive of acute coronary syndrome, in conjunction with 
physical examination and ECG. Because of the speciﬁ  city 
of cTn for myocardial damage, a single cTn above the 
decision limit, along with clinical evidence, is indicative 
of myocardial injury (Möckel et al 1998; Panteghini 2004; 
Antman et al 2004; Melanson et al 2007; Morrow et al 2007). 
The latter holds true regarding our study, where mean levels 
of peak serum CPK, AST, and LDH were signiﬁ  cantly 
higher in patients with acute ﬁ  rst-ever MI compared with 
patients with CAD without MI and controls (p  0.001). 
Most important was the demonstration of positive linear 
correlation between peak serum CPK, AST, and LDH with 
Gensini score (Spearman’s ρ = 0.389, p  0.001; Spearman’s 
ρ = 0.391, p  0.001; and Spearman’s ρ = 0.366, p  0.001, 
respectively). Therefore, higher myocardial enzyme peak 
serum levels were related to increased severity of CAD, 
represented by Gensini score.
Tissue necrosis is also the initiating event of a subsequent 
inﬂ  ammatory process that accounts for a signiﬁ  cant increase 
in serum inﬂ  ammatory markers (CRP, ﬁ  brinogen, ESR, and 
peripheral WBC count) noticed in patients with acute MI. In 
our study, the mean value of CRP was signiﬁ  cantly higher in 
patients with acute MI than in patients with CAD without MI 
and controls (p  0.001). CRP values correlated positively 
with CAD severity estimated by Gensini score (Spearman’s 
ρ = 0.418, p  0.001). In consideration of the important 
role that inﬂ  ammatory processes play in determining plaque 
stability, recent work has focused on whether plasma markers 
of inﬂ  ammation may help improve risk stratiﬁ  cation. Of 
these markers, CRP has been the most widely studied, 
and there is now robust evidence that CRP is a strong 
predictor of cardiovascular risk among apparently healthy 
individuals, patients undergoing elective revascularization 
procedures, and patients presenting with acute coronary 
syndromes (Berk et al 1990; Neumann et al 1995; Mendall 
et al 2000; Sepulveda and Mehta 2005; Brunetti et al 2006; 
Blake and Ridker 2007).
Inﬂ  ammation is a recognized key component of acute 
coronary syndromes. Such pathogenetic achievement has led 
to the use of inﬂ  ammatory cells and proteins as prognostic 
markers in these syndromes. A number of markers have 
been proposed, including proinflammatory cytokines 
such as interleukin-6, interleukin-1, and tumor necrosis 
factor-α, adhesion molecules such as intracellular adhesion 
molecule-1 and vascular adhesion molecule-1 and markers 
of cell activation. Although all are of scientiﬁ  c interest, the 
clinical use of these markers is limited by their high cost, 
low availability, and unfavorable biological proﬁ  le. Circu-
lating levels of CRP rise during the acute-phase response to 
tissue injury, infection, and inﬂ  ammation (Berk et al 1990; 
Danesh et al 1999; Mendall et al 2000; Biasucci et al 2004; 
Sepulveda and Mehta 2005; Brunetti et al 2006; Blake and 
Ridker 2007). Conversely, CRP, the prototypic acute phase 
protein, and to a lesser extent ﬁ  brinogen, have been proven 
to be reliable and important markers of risk in ischemic heart 
disease. CRP has been consistently found to be independent 
from other risk factors and to have an incremental value 
beyond the common risk factors and biochemical markers 
of risk, including troponin (Berk et al 1990; Danesh et al 
1999; Mendall et al 2000; Biasucci et al 2004; Sepulveda 
and Mehta 2005; Brunetti et al 2006; Blake and Ridker 
2007). CRP has been shown to exert proatherogenic effects 
on vascular cells exempliﬁ  ed by increasing the secretion 
of monocyte chemoattractant protein (Pasceri et al 2001), 
reducing nitric oxide bioactivity (Venugopagal et al 2002), 
and inducing adhesion molecules, such as vascular cell 
adhesion molecule-1, intercellular adhesion molecule-1, and 
E-selectin (Pasceri 2000).
Vascular inﬂ  ammation can be limited by antiinﬂ  ammatory 
counterregulatory mechanisms that maintain the integrity and 
homeostasis of the vasculature (Tedgui and Mallat 2001). 
HDL encompasses potent antiinflammatory properties 
which could account for the protective effect against ath-
erogenesis (Cockerill et al 1995). Εpidemiological and 
clinical studies showed that HDL concentration is often 
inversely correlated with the plasma levels of CRP, in 
atherosclerotic cardiovascular diseases (Ridker et al 2000). 
HDL molecules have an established role in the regression Clinical Interventions in Aging 2008:3(4) 708
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processes of atherosclerosis as well as a putative role as 
antiinﬂ  ammatory agents. Elevation of CRP values in familial 
hypoalphalipoproteinemia, in the absence of signs and 
symptoms of local or systemic inﬂ  ammation or systemic 
or recurrent disease, may suggest an upregulation of 
proinﬂ  ammatory mechanisms, which is further exacerbated 
by the presence of coronary atherosclerotic disease 
(Sampietro et al 2002). Furthermore, among subjects with 
a visible lesion or stenosis in coronary arteries, those with 
low HDL cholesterol or smokers are more likely to develop 
MI (Sun et al 2006).
In our study, a signiﬁ  cant reciprocal correlation between 
serum HDL and CRP and between serum HDL and Gensini 
score was demonstrated indicating a possible causal effect. 
These observations concerning HDL, Gensini score, and CRP 
merit further investigation in order to distinguish between 
statistical epiphenomena and possible causal relation.
Wadham and colleagues (2004) support that HDL via 
oxidation of its principal phospholipid neutralizes the proin-
ﬂ  ammatory potential of CRP in endothelial cells, revealing 
a balance between antiinﬂ  ammatory and proinﬂ  ammatory 
actions within the vascular wall. Factors that decrease the 
quantity and/or quality of  HDL, such as obesity, diabetes, and 
age, are often associated with increased CRP concentration 
(Chambers et al 2001; Wadham et al 2004), which could 
ultimately disturb the antiinﬂ  ammatory and proinﬂ  ammatory 
balance to contribute to the development of inﬂ  ammatory 
cardiovascular diseases. In a prospective study by Tarchalski 
and colleagues (2003) in angina pectoris patients with no pre-
vious MI, severity of coronary atherosclerosis was positively 
correlated with total cholesterol, LDL cholesterol, and 
triglycerides and negatively correlated with HDL cholesterol. 
In our study a negative association between serum HDL and 
Gensini score, the index of CAD severity is also established 
in patients with CAD without infarction, in patients with 
acute MI and controls.
Fibrinogen levels were also higher in patients with acute 
MI compared to other groups, yet the difference did not yield 
statistical signiﬁ  cance in our sample (p = 0.14). Signiﬁ  cant 
correlation was demonstrated regarding ﬁ  brinogen levels 
and Gensini score (Pearson correlation = 0.224, p = 0.037). 
Fibrinogen levels play a critical role in both blood clot 
formation and vascular wall inﬂ  ammation while genetic 
heterogeinity between individuals further determines suscep-
tibility to CAD (Mannila 2006; Omran and Asadollahi 2007). 
Serum ﬁ  brinogen is also related to CAD and considered to 
be an independent predictor of acute MI. Fibrinogen was 
demonstrated, more than 40 years ago, to be elevated among 
patients with acute thrombosis (Eidelman and Hennekens 
2003). The ﬁ  rst prospective study to show an association 
between ﬁ  brinogen levels and subsequent cardiovascular 
disease risk was the Gothenburg Heart Study from Sweden 
in 1984 (Wilhelmsen et al 1984). In the Northwick Park 
Heart Study from the UK (Meade et al 1986), ﬁ  brinogen 
and factor VII appeared to be as effective as total cholesterol 
in predicting future risk of coronary heart disease. In the 
European Concerted Action on Thrombosis and Disabilities 
Angina Pectoris Study (Ross 1999), higher levels of 
ﬁ  brinogen predicted subsequent acute coronary syndromes 
while lower levels, despite elevated cholesterol levels, were 
associated with lower risks of acute coronary syndromes.
In our study mean values peripheral WBC counts were 
signiﬁ  cantly higher in patients with acute MI than in patients 
with CAD without MI and controls (p  0.001). Signiﬁ  cant 
correlation was found regarding WBC count and Gensini 
score (Spearman’s ρ = 0.258 p = 0.004), indicating a strong 
association of leukocytosis with CAD severity, especially 
in patients with acute MI. Correlation of the leukocyte 
count with CAD and investigations into the utility of the 
leukocyte count as a risk factor and prognostic indica-
tor in patients with CAD are consistent with the current 
concept that atherosclerosis is an inﬂ  ammatory disease 
(Pearson et al 2003; Pai et al 2004; Madjid et al 2004; Jia 
et al 2005). Leukocytosis affects CAD through multiple 
pathologic mechanisms that mediate inﬂ  ammation, cause 
proteolytic and oxidative damage to the endothelial cells, 
plug the microvasculature, induce hypercoagulability, and 
promote infarct expansion. In summary, leukocytosis has 
been consistently shown to be an independent risk factor 
and prognostic indicator of future cardiovascular outcomes, 
regardless of disease status. The leukocyte count is inex-
pensive, reliable, easy to interpret, and ordered routinely 
in inpatient and outpatient settings (Madjid et al 2004). 
The association of WBC count with the angiographical 
characteristics of coronary atherosclerosis, as estimated by 
Gensini score, strongly suggests that granulocytosis may 
play a role in the development of coronary atherosclerosis 
(Jia et al 2005).
ESR values were also higher in patients with acute 
MI compared to other groups, but this difference did not yield 
statistical signiﬁ  cance in our sample (p = 0.33). However sig-
niﬁ  cant correlation regarding ESR and Gensini score was dem-
onstrated, indicating the importance of ESR values in patients 
with severe CAD (Spearman’s ρ = 0.270, p = 0.015). In 1988 
the International Committee for Standardization in Hematol-
ogy suggested that the ESR might be a particularly robust Clinical Interventions in Aging 2008:3(4) 709
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and appropriate test for monitoring chronic inﬂ  ammatory 
processes since it is sensitive to both ﬁ  brinogen and immuno-
globulins (ICSH 1988). Accordingly, a fast and inexpensive 
ESR test might be a valuable tool for assessing the strength 
of the inﬂ  ammatory response associated with atherosclerosis, 
and might conceivably carry important short- and long-term 
prognostic information (Erikssen et al 2000). The ESR is 
a strong predictor of coronary heart disease mortality, and 
appears to be a marker of aggressive forms of coronary heart 
disease. The ESR probably gives substantial information in 
addition to that given by ﬁ  brinogen on the risk of coronary 
heart disease death (Erikssen and Mundal 1982).
Study limitations
A major limitation of our study was the selection of  “control” 
patients. Although all patients in this group were subjected 
to coronary angiography that did not reveal critical coronary 
vessel stenoses the majority had underlying cardiovascular 
disease including dilated cardiomyopathy, valvular disorders, 
etc. Therefore, although a negative coronary angiogram 
eliminated the possibility of coexisting CAD, these subjects 
had some form of cardiological condition rendering their 
recruitment in the control group problematic. For practical 
reasons and since the main criterion for patient recruitment 
into study groups was the presence or absence of CAD, we 
regarded these patients as “controls,” based in the absence 
of CAD, according to angiographic ﬁ  ndings.
Conclusions
The objective of our study was to identify correlations 
between serum levels of myocardial enzymes, serum lipids, 
and inﬂ  ammatory biomarkers, with CAD severity reﬂ  ected 
by Gensini score, in Greek patients submitted to coronary 
angiography.
Signiﬁ  cant positive correlations between angiographic 
findings, peak serum myocardial enzyme levels, and 
inflammatory biomarkers were identified. Myocardial 
enzyme serum levels and inﬂ  ammatory biomarkers not 
only increased in the setting of an acute coronary event, 
but there was also a quantitative correlation with the extent 
of myocardial damage and CAD severity, according to 
angiographic findings (Gensini score). In this study, a 
reciprocal association between HDL levels and CAD severity 
(Gensini score) was established and an inverse correlation 
between serum HDL and CRP levels was demonstrated.
The correlation between peak serum myocardial enzyme 
levels (CPK, AST, LDH), markers of inﬂ  ammation (CRP, 
ﬁ  brinogen, ESR, WBC) and HDL with severity of CAD 
evaluated by Gensini score shown in our study, could also 
convey important prognostic signiﬁ  cance regarding the 
clinical setting. Evidence from our study demonstrated that 
simple biochemical assays provide an adequate estimation 
of CAD severity due to their correlation with Gensini score 
in hospitalized patients. The latter holds true, especially in 
patients submitted to coronary angiography due to acute MI. 
Serum enzyme levels and inﬂ  ammatory indexes could be 
used to obtain a comprehensive view of the infarct size and 
severity of vascular stenotic lesions.
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